Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–1 of 1 stories
FDA grants Breakthrough Therapy Designation to Ipsen’s IPN60340 (ICT01) for first-line treatment of unfit acute myeloid leukemia. This designation aims to expedite the development and review process for this promising therapy.
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.